

## Sterne Kessler ATTORNEYS AT LAW



Robert Greene Sterne Robert W. Esmond Michael B. Ray Robert F. Sokohl Michael O. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherston Michael V. Messinger

Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Kraus Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Pattersor Vincent L. Capuano Albert J. Fasulo II\*

Judith U. Kim

Cottingham M. Lhulier G. Maze

Registered Patent Agents\* Karen R. Markowicz Andrea J. Kamage Nancy J. Leith Ann E. Summerfield Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Angelique G. Uy Boris A. Matvenko Bryan L. Skelton Robert A. Schwa Robert A. Schwartzman John J. Figueroa Timothy A. Doyle Jennifer R. Mahalingappa

Samuel L. Fox Kenneth C. Bass III

- Admitted only in Maryland Admitted only in Virginia Admitted only in Texas Practice Limited to
- Federal Agencies

October 18, 2002

WRITER'S DIRECT NUMBER: (202) 371-2625 **INTERNET ADDRESS:** ESTEFFE@SKGF.COM

Art Unit 1651

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Utility Patent Application

Appl. No. 09/881,204; Filed: June 15, 2001

**Pluripotent Mammalian Cells** For:

Inventors:

DOMINIKO et al.

Our Ref:

1954.0010001/EKS/PSC

RECEIVED

OCT 2 1 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action are the following documents:

- First Supplemental Information Disclosure Statement; 1.
- 2. Form PTO-1449 (24 sheets citing 79 documents);
- 79 documents cited in Form PTO-1449 attached; and 3.
- 4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLEP, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicants Registration No. 36,688

EKS/PSC/lam **Enclosures** 

::ODMA\MHODMA\SKGF\_DC1;66495;1

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 † 202.371.2540: www.skgf.com







In re application of:

DOMINIKO, et al.

Appl. No. 09/881,204

Filed: June 15, 2001

For: Pluripotent Mammalian Cells

Confirmation No. 5122

Art Unit: 165

Examiner: T. Ton

Atty. Docket: 1954.0010001/EKS/PSO

## First Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on July 17, 2002 in connection with the above-captioned application. A copy of each document is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not

be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicants Registration No. 36,688

Date: 10/18/02

1100 New York Avenue, N.W.

Suite 600

Washington, D.C. 20005-3934

(202) 371-2600

SKGF\_DC1:64345.1